Effective from the first dose, regardless of HK severity2

Greatest K+ reduction observed in patients with severe hyperkalemia2 

Adapted from Di Palo et al. 2022.

Significant reduction in K+

Significant mean reduction in serum K+ levels of 0.50 mEq/L from baseline (P<0.001; primary endpoint), within 6 hours after Veltassa® was administered

Significant reduction in K+
Significant mean reduction in serum K+ levels of 0.50 mEq/L from baseline (P<0.001; primary endpoint), within 6 hours after Veltassa® was administered
Optional Header
Real-world retrospective cohort study of 881 patient encounters for acute, non-life threatening hyperkalemia treated in emergency departments (n=152), inpatient units (n=679), and intensive care units (n=50) at the Montefiore Medical Centre. Mean baseline serum K+ levels of 5.60 mEq/L. The lowest dose of Veltassa® was 8.4 g used in 721 encounters (81.8%), 16.8 g was used in 154 encounters (17.5%), and 25.2 g was used in 6 encounters (0.7%). In the 24 hours after the initial administration of Veltassa®, in 725 encounters (82.3%), patients received no further doses of K+ binders, whereas in 137 encounters (15.5%), patients received 1 additional dose and in 19 encounters (2.2%), patients received 2 or more additional doses. 
Optional Paragraph Text: Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed dapibus quam sed ipsum varius imperdiet.
Optional Paragraph Text: Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed dapibus quam sed ipsum varius imperdiet.